All News

In 2022 and 2023, there are a number of big therapies losing patent exclusivity, which opens the door to generics that could save as much as $30 billion.

Conversations are ongoing between CMS and patient advocates on how accountable care organizations (ACOs) and similar programs can better interface with beneficiaries.

Orly Vardeny, PharmD, MS, core investigator, Center for Care Delivery and Outcomes Research, and associate professor of Medicine, University of Minnesota Medical School, discusses key barriers to access of novel therapies and what sessions she’s looking forward to during the American College of Cardiology's (ACC) 71st Annual Scientific Session.

While the pandemic will have lasting impacts on the US health care market, much of it has bounced back and returned to normal, said Doug Long, MBA, of IQVIA, during the Thursday keynote at the Academy of Managed Care Pharmacy annual meeting.

This subanalysis of participant data from the OPEN project investigated relationships between glycemic levels and insulin requirements among women with type 1 diabetes and phases of their menstrual cycle.

Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains how public and private employers can take advantage of the National Diabetes Prevention Program (DPP).

Younger and older patients with noneosinophilic chronic rhinosinusitis (CRS) with nasal polyps showed significant differences in preoperative blood eosinophil levels and postoperative modified Lund-Kennedy scores.

Although the medication therapy management program in Tennessee's Medicaid population did not reduce costs, some adherence to medication improved and emergency department visits improved.

Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed some of the regulatory and legal hurdles that generic and biosimilar companies have to face on the road to market launch.

CMS-1773-P will establish a budget-neutral payment policy to smooth year-to-year changes in the hospice wage index; President Joe Biden pushes for $22 billion in COVID-19 funding from Congress; an FDA advisory panel said there is not enough evidence supporting the efficacy of the amyotrophic lateral sclerosis (ALS) treatment AMX0035.

Levosimendan appeared to increase in-hospital survival rates, although no long-term survival benefit was reported, among patients with comorbid heart failure and connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH).

Patients with severe asthma continue to have residual disease despite initiating treatment with biologics, and severe uncontrolled asthma is associated with higher economic burden compared with controlled asthma, according to 2 posters.

Investigators say it may soon be possible to design therapies better at staving off resistance among patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM), which is an incurable disease.

Racial and ethnic health disparities are documented and substantial, but the data are out there to create programs that successfully address these disparities, said panelists.

A study conducted in China found that infants whose mother has depression, anxiety, or a sleep disorder are more likely to have sleep disorders themselves.

A new FAIR Health white paper containing the fifth annual edition of FH Healthcare Indicators and FH Medical Price Index was released, showing a dramatic increase in telehealth utilization from 2019 to 2020.

Development of FGFR inhibitors, which target fibroblast growth factor receptors, is among the most important advances in the treatment of cholangiocarcinoma.

Two studies presented at the annual meeting of the American College of Cardiology show the safety and effectiveness of regular coffee consumption in regard to cardiovascular disease and heart disease, as well as mortality.

Michael Ciarametaro, MBA, vice president of research at the National Pharmaceutical Council, discusses the balance between lowering drug prices and encouraging innovation in new drug classes for serious diseases.

Longer drug survival was associated with interleukin-17 (IL-17) inhibitors vs tumor necrosis factor (TNF) inhibitors in the treatment of psoriasis and psoriatic arthritis, but persistence rates for first-line biologics overall remained low.

A 6-month chronic obstructive pulmonary disease (COPD) care management collaborative helped reduce COPD-related revisits and save hospitals money.

UnitedHealth Group will buy LHC Group for $5.4 billion as part of its home health care expansion plan; the FDA approved a second COVID-19 booster dose for adults aged 50 and older; a study found differing patterns of clinic and emergency department acute-care use between White, Black, and Latino or Hispanic children with asthma.

A literature review pointed out the limited current research that has been conducted on how to manage pruritus in patients with chronic kidney disease (CKD) treated with hemodialysis, suggesting that more data is needed to improve symptom burden in these patients.

The American College of Cardiology will host its annual conference beginning Friday, April 1, 2022, both in-person and online.

Relapse remains a daunting reality in multiple myeloma, but clinicians have more tools to work with to fight the disease.

A new review article shows diabetes and hypertension are linked with arrhythmia and chronic kidney disease (CKD), but several other less common causes also exist.

The authors say delivering FOLFOX via transarterial infusion could be a “perfect option for treating intrahepatic cholangiocarcinoma before patients receive targeted therapy, immunotherapy, or radiotherapy.

The COVID-19 pandemic has affected the mental health of health care workers as well as the general population, creating a significant impact on sleep quality.